Browse online courses and resources on Genitourinary Cancers.

All Genitourinary Courses
Collapse 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for genitourinary cancer, including kidney, bladder and prostate cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for genitourinary cancer (kidney, bladder and prostate cancers), and how to identify and manage common side effects of immunotherapy agents.

 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

 

Faculty
Lauren Harshman, MD

Assistant Professor and Co-director, Kidney Cancer Program

Dana-Farber Cancer Institute

 

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for common approaches to cancer immunotherapy.
  • Implement cancer immunotherapy treatment for genitourinary cancers. 
  • Identify the appropriate clinical management of common side effects of immunotherapy agents.

 


SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


 

Continuing Education Information

 

Credit Available: March 28, 2019 - March 28, 2020

Approximate Time to Complete:  45 minutes

 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

sitc_log_color.png PIM_logo.png

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-608-H01-P)

Type of Activity: Knowledge


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

Faculty
Lauren Harshman, MD - Advisory/Research to Bayer, Exelixis, Genentech, Dendreon/Valient, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck, Bristol-Meyers Squib, Jannsen, Sotio, Takeda, Sanofi, Novartis, Applied Clinical Education, PER


Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period March 28, 2019 through March 28, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Complete the post-test and survey.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

 

Original Course Date: March 28, 2019

Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpg

    Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

    The Immunotherapy for the Treatment of Genitourinary Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of Genitourinary Malignancies. The module also includes case studies on immunotherapy for the treatment of Genitourinary Malignancies.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Lenard J. Appleman, MD, PhD

    Associate Professor of Medicine

    UPMC Hillman Cancer Center

     

    Educational Objectives

    1. Describe the rationale for common approaches to cancer immunotherapy for genitourinary malignancies 
    2. Identify the appropriate clinical management of common side effects of immunotherapy agents
    3. Implement cancer immunotherapy for genitourinary malignancies
    4. Become familiar with clincial data on the efficacy of approved therapies
    5. Recognize patient selection criteria for approved therapies
    6. Select appropriate dosing and sequencing of approved therapies (including timing and combination approaches)

    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

     

    (Universal Activity Number - JA4008162-9999-19-732-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Leonard J. Appleman, MD, PhD: Contracted Research - Astellas, BMS, Bayer, Exolius, Merck, Roche

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 17, 2019 through April 17, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: January 31, 2018

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Advances in Cancer Immunotherapy™ 2017 Video Series: Immunotherapy for the Treatment of Genitourinary Cancers

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are used as content for online courses. One video has been selected for each topic of the 2017 ACI program (twelve total modules).

     

    The online modules will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.


    This course is Module 4 of 12: The Immunotherapy for the Treatment of Genitourinary Cancers. This course covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of genitourinary cancers. The course also includes case studies on immunotherapy for the treatment of genitourinary cancers.

     

    Target Audience

    These modules have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Availabe: Oct. 6, 2017- September 30, 2018

     

    Other Available Modules

    Module 1: Basic Principles of Cancer Immunotherapy

    Module 2: Immunotherapy for the Treatment of Melanoma

    Module 3: Immunotherapy for the Treatment of Lung Cancer

    Module 4: Immunotherapy for the Treatment of Genitourinary Cancers

    Module 5: Immunotherapy for the Treatment of Hematologic Malignancies

    Module 6: Immunotherapy for the Treatment of Head and Neck Cancers

    Module 7: Effective Practices for Incorporating Immunotherapy into Hospital Operations 

    Module 8: Coverage and Reimbursement Challenges and Strategies

    Module 9: Mechanisms of Immune-Related Adverse Events

    Module 10: Nursing Perspective on irAEs: Patient Education, Monitoring and Management 

    Module 11: Management and Mitigation of irAEs for Immunotherapy Prescribers 

    Module 12: Identification and Management of Immune-Related Adverse Events in the Emergency Setting

    Original Course Date: October 06, 2017
    MORE INFOMORE INFO Advances in Cancer Immunotherapy™ 2017 Video Series: Immunotherapy for the Treatment of Genitourinary Cancers
    Collapse Cases in mRCC: Steps to Optimizing Care

    Access Course

    Cases in mRCC: Steps to Optimize CareDr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).

     

    This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Dec. 19, 2018 -  Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Cases in mRCC: Steps to Optimizing Care
    Collapse Kidney Cancer Treatments: Is One Option Better Than Another for Me?

    Access Course

     

    888494-fig1.pngThis article is for people who’ve had treatment for kidney cancer that has now spread, called metastatic renal cell carcinoma (mRCC). It’s also for their care partners and others who want to learn more about the next treatment choices. The goal is to learn about all your treatment options so you can better decide with your care team what’s right for you.

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Kidney Cancer Treatments: Is One Option Better Than Another for Me?
    Collapse Management of Advanced Bladder Cancer: What You Should Know

    Access Course

     

    This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

     

     

     

     

     

    You will learn about:

     

    • What chemotherapy is and how it is used to treat advanced bladder cancer
    • What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
    • The potential side effects of chemotherapy and checkpoint inhibitors
    • Why the side effects from chemotherapy and checkpoint inhibitors are different
    • Questions to ask your doctor

     

    Available beginning: April 26, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 26, 2019
    MORE INFOMORE INFO Management of Advanced Bladder Cancer: What You Should Know
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse Patient-Centered Care in Advanced Bladder Cancer

    Access Course

     

    Patient-Centered Care in Advanced Bladder CancerExperts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.

    The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Apr. 30, 2019- Apr. 30, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 30, 2019

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Patient-Centered Care in Advanced Bladder Cancer